Reirradiation for Locoregional Recurrent Breast Cancer

Fattahi, Sayeh; Ahmed, Safia K.; Park, Sean S.; Petersen, Ivy A.; Shumway, Dean A.; Stish, Bradley J.; Yan, Elizabeth; Remmes, Nicholas B.; Mutter, Robert W.; Corbin, Kimberly S.

doi:10.1016/j.adro.2020.100640

Cited by 30 publications

(23 citation statements)

References 43 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our most downloaded paper at this time is a paper on breast cancer reirradiation from Fattahi et al 5 Social media focused articles and analyses of professional issues related to resident training and the job market are highly read. Included in this issue is a report characterizing Twitter influencers in radiation oncology by Valle et al that is one of our most highly read papers.…”

mentioning

confidence: 99%

WITHDRAWN: ASTRO's Advances in Radiation Oncology in 2022

Miller

Tsai

2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

mentioning

confidence: 99%

WITHDRAWN: ASTRO's Advances in Radiation Oncology in 2022

Miller

Tsai

2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…Of note, the 1-year local recurrence free survival (LFRS) and overall survival (OS) were 93% and 97%, respectively, with only 16% of patients experiencing grade 3 adverse events (25). A recent retrospective analysis of 74 patients treated with PBT for reRT showed a similarly low rate of grade 3 toxicity at any point (13%) (26), which compared favorably with historical toxicity incidences for photon re-irradiation (27).…”

Section: Clinical Outcomes For Proton Therapymentioning

confidence: 99%

Particle Therapy for Breast Cancer: Benefits and Challenges

et al. 2021

View full text Add to dashboard Cite

Hadron therapy with protons and carbon ions is widely attracting interest as a potential competitor of conventional photon radiotherapy. Exquisite dose distribution of charged particles allows for a higher local control of the tumor and lower probability of damage to nearby healthy tissues. Heavy ions have presumed biological advantages rising from their high-linear energy transfer (LET) characteristics, including greater cell-killing effectiveness and reduced heterogeneity dependence of radiation response. Although these advantages are clear and supported by data, only 18.0% of proton and carbon ion radiotherapy (CIRT) facilities in Europe are treating breast cancers. This review summarizes the physical and radiobiological properties of charged particles, clinical use of particle beam for breast cancer, and suggested approaches to overcome technical and financial challenges.

show abstract

“…While avoidance of radiation is often the strongest recommendation, in some very high-risk circumstances, radiotherapy is necessary and particle therapy can be utilized to reduce extraneous doses. In addition, in the setting of reirradiation, sparing of normal healthy tissues without compromising target coverage is often critical [ 45 ] ( Figure 4 ). Finally, adolescent and young adult patients are widely accepted to have the most to gain from the reduced integral dose from particle therapy.…”

Section: Proton Therapy: Rationale and Specific Clinical Indicationsmentioning

confidence: 99%

Particle Therapy for Breast Cancer

Kowalchuk

Corbin

Jimenez

2022

Cancers

Self Cite

View full text Add to dashboard Cite

Particle therapy has received increasing attention in the treatment of breast cancer due to its unique physical properties that may enhance patient quality of life and reduce the late effects of therapy. In this review, we will examine the rationale for the use of proton and carbon therapy in the treatment of breast cancer and highlight their potential for sparing normal tissue injury. We will discuss the early dosimetric and clinical studies that have been pursued to date in this domain before focusing on the remaining open questions limiting the widespread adoption of particle therapy.

show abstract

Reirradiation for Locoregional Recurrent Breast Cancer

Cited by 30 publications

References 43 publications

WITHDRAWN: ASTRO's Advances in Radiation Oncology in 2022

WITHDRAWN: ASTRO's Advances in Radiation Oncology in 2022

Particle Therapy for Breast Cancer: Benefits and Challenges

Particle Therapy for Breast Cancer

Contact Info

Product

Resources

About